Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spectrin beta chain, non-erythrocytic 5 (SPTBN5) is a large cytoskeletal protein encoded by the SPTBN5 gene on chromosome 15q15.1, containing 68 exons and producing a 3674-amino acid protein[1][2][3]. It is a member of the spectrin family responsible for linking membrane proteins and lipids to the actin cytoskeleton, thereby contributing to cell shape, mechanical stability, and intracellular transport[1][2][3]. SPTBN5 forms oligomers with alpha-spectrin and contains calponin homology domains (actin binding), spectrin repeats (flexibility and self-association), and a C-terminal pleckstrin homology domain (membrane recruitment)[1][3]. It is ubiquitously expressed, with significant roles in the brain and other organs[1]. Recent genetic data link biallelic SPTBN5 loss-of-function mutations to a syndrome characterized by intellectual disability, developmental delay, seizures, and, variably, aggressive behavior and mild dysmorphic features[1]. Other family members of spectrin are implicated in erythroid and neurological disorders, but SPTBN5 currently lacks therapeutic targeting or confirmed drug interactions[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spectrin beta chain, non-erythrocytic 5 (SPTBN5).